Legal Status
Legal Status
Notice
Agency Information Collection Activities; Submission for OMB Review; Comment Request; New Animal Drug Application, Form FDA 356 V
A Notice by the Food and Drug Administration on
Document Details
Information about this document as published in the Federal Register.
- Printed version:
- Publication Date:
- 05/08/2001
- Agencies:
- Food and Drug Administration
- Dates:
- Submit written comments on the collection of information by June 7, 2001.
- Comments Close:
- 06/07/2001
- Document Type:
- Notice
- Document Citation:
- 66 FR 23266
- Page:
- 23266 (1 page)
- Agency/Docket Number:
- Docket No. 01N-0006
- Document Number:
- 01-11454
Document Details
-
Enhanced Content - Table of Contents
This tables of contents is a navigational tool, processed from the headings within the legal text of Federal Register documents. This repetition of headings to form internal navigation links has no substantive legal effect.
Enhanced Content - Table of Contents
-
Enhanced Content - Submit Public Comment
- This feature is not available for this document.
Enhanced Content - Submit Public Comment
-
Enhanced Content - Read Public Comments
Enhanced Content - Read Public Comments
-
Enhanced Content - Sharing
- Shorter Document URL
- https://www.federalregister.gov/d/01-11454 https://www.federalregister.gov/d/01-11454
Enhanced Content - Sharing
-
Enhanced Content - Document Tools
These tools are designed to help you understand the official document better and aid in comparing the online edition to the print edition.
-
These markup elements allow the user to see how the document follows the Document Drafting Handbook that agencies use to create their documents. These can be useful for better understanding how a document is structured but are not part of the published document itself.
Display Non-Printed Markup Elements
Enhanced Content - Document Tools
-
-
Enhanced Content - Developer Tools
This document is available in the following developer friendly formats:
- JSON: Normalized attributes and metadata
- XML: Original full text XML
- MODS: Government Publishing Office metadata
More information and documentation can be found in our developer tools pages.
Enhanced Content - Developer Tools
Published Document
This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA) is announcing that the proposed collection of information listed below has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.
DATES:
Submit written comments on the collection of information by June 7, 2001.
ADDRESSES:
Submit written comments on the collection of information to the Office of Information and Regulatory Affairs, OMB, New Executive Office Bldg., 725 17th St. NW., rm. 10235, Washington, DC 20503, Attn: Wendy Taylor, Desk Officer for FDA.
Start Further InfoFOR FURTHER INFORMATION CONTACT:
Denver Presley, Office of Information Resources Management (HFA-250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-1472.
End Further Info End Preamble Start Supplemental InformationSUPPLEMENTARY INFORMATION:
In compliance with 44 U.S.C. 3507, FDA has submitted the following proposed collection of information to OMB for review and clearance.
New Animal Drug Application, Form FDA 356 V— 21 CFR Part 514 (OMB Control No. 0910-0032)—Extension
FDA has the responsibility under the Federal Food, Drug, and Cosmetic Act (the act) for the approval of new animal drugs that are safe and effective. Section 512(b) of the act (21 U.S.C. 360b(b)) requires that a sponsor submit and receive approval of a new animal drug application (NADA), before interstate marketing is allowed. The regulations implementing statutory requirements for NADA approval have been codified under 21 CFR part 514. NADA applicants generally use a single form, FDA 356 V. The NADA must contain, among other things, safety and effectiveness data for the drug, labeling, a list of components, manufacturing and controls information, and complete information on any methods used to determine residues of drug chemicals in edible tissues. While the NADA is pending, an amended application may be submitted for proposed changes. After an NADA has been approved, a supplemental application must be submitted for certain proposed changes, including changes beyond the variations provided for in the NADA and other labeling changes. An amended application and a supplemental application may omit statements concerning which no change is proposed. This information is reviewed by FDA scientific personnel to ensure that the intended use of an animal drug, whether as a pharmaceutical dosage form, in drinking water, or in medicated feed, is safe and effective. The respondents are pharmaceutical firms that produce veterinary products and commercial feed mills.
FDA estimates the burden of this collection of information as follows:
21 CFR section | No. of respondents | Annual frequency per response | Total annual responses | Hours per response | Total hours |
---|---|---|---|---|---|
514.1 and 514.6 | 190 | 8.33 | 1,582 | 211.6 | 334,751 |
514.8 | 190 | 8.33 | 1,582 | 30 | 47,460 |
514.11 | 190 | 8.33 | 1,582 | 1 | 1,582 |
Total | 383,793 | ||||
1 There are no capital costs or operating and maintenance costs associated with this collection of information. |
The estimate of the burden hours required for reporting are based on fiscal year 1999 data. The burden estimate includes original NADAs, supplemental NADAs, and amendments to unapproved applications.
Start SignatureDated: May 2, 2001.
William K. Hubbard,
Senior Associate Commissioner for Policy, Planning, and Legislation.
[FR Doc. 01-11454 Filed 5-7-01; 8:45 am]
BILLING CODE 4160-01-S